Redeye provides a research update following the Q4 report published by OncoZenge earlier today. While the company reported increased quarterly expenses, this is explained by completed GMP manufacturing and intensified preparations for the upcoming pivotal phase III trial. With the previous liquidity issues now resolved, the CTA application submitted and being bolstered by encouraging insights from the recent engagement study with UCLA, we have a positive outlook on the year ahead for OncoZenge.
LÄS MER
